-
161
Golgi fragmentation – One of the earliest organelle phenotypes in Alzheimer’s disease neurons
Published 2023-02-01Get full text
Article -
162
-
163
Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer’s Disease Management
Published 2023-12-01Get full text
Article -
164
Localized proteomic differences in the choroid plexus of Alzheimer's disease and epilepsy patients
Published 2023-07-01Get full text
Article -
165
Neuroprotective role of epigallocatechin-3-gallate, albeginin and melanoxetin in alzheimer's disease
Published 2025-02-01Get full text
Article -
166
Inflammatory Cascade in Alzheimer’s Disease Pathogenesis: A Review of Experimental Findings
Published 2021-09-01Get full text
Article -
167
Insights into the changes in the proteome of Alzheimer disease elucidated by a meta-analysis
Published 2021-12-01Get full text
Article -
168
Asymmetric amyloid deposition in preclinical Alzheimer’s disease: A PET study
Published 2022-01-01Get full text
Article -
169
Can an Infection Hypothesis Explain the Beta Amyloid Hypothesis of Alzheimer’s Disease?
Published 2018-07-01Get full text
Article -
170
Neutrophil-vascular interactions drive myeloperoxidase accumulation in the brain in Alzheimer’s disease
Published 2022-03-01Get full text
Article -
171
Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer's disease
Published 2014-11-01Get full text
Article -
172
-
173
-
174
Synthesis and Characterization of Memantine-Loaded Niosomes for Enhanced Alzheimer’s Disease Targeting
Published 2025-02-01Get full text
Article -
175
Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer’s Disease
Published 2021-05-01“…Dr., Ikerbasque, The Basque Foundation for Science Bilbao, Spain and BCAM - The Basque Center for Applied Mathematics, Mathematical, Computational and Experimental (MCEN) Research Group, Alameda de Mazarredo 14, Bilbao, Bizkaia, Basque-Country, 48009, SpainTel +34 946 567 842Email srodrigues@bcamath.orgAbstract: Alzheimer’s disease (AD) is the most common form of dementia and aging is the most common risk factor for developing the disease. …”
Get full text
Article -
176
APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer's disease
Published 2020-06-01“…The ε4 allele of Apolipoprotein (APOE4) is the strongest genetic risk factor for Alzheimer's disease (AD), the most common form of dementia. …”
Get full text
Article -
177
-
178
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
Published 2021-06-01Get full text
Article -
179
Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease
Published 2017-03-01“…Gargi Ganguly,1 Sasanka Chakrabarti,2 Uttara Chatterjee,1 Luciano Saso3 1Department of Pathology, Institute of Post Graduate Medical Education and Research, Kolkata, 2Department of Biochemistry, ICARE Institute of Medical Sciences and Research, Haldia, West Bengal, India; 3Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, Rome, Italy Abstract: Alzheimer’s disease and Parkinson’s disease are two common neurodegenerative diseases of the elderly people that have devastating effects in terms of morbidity and mortality. …”
Get full text
Article -
180